HMP Shunt & Uronic Acid Pathway

The hexose monophosphate (HMP) shunt and the uronic acid pathway are two alternative routes of glucose-6-phosphate oxidation that run parallel to glycolysis without producing ATP. Their job is to generate NADPH (reducing power) and ribose-5-phosphate (for nucleotides), plus glucuronic acid for detoxification and proteoglycan synthesis — making them a recurring NEET PG favourite through G6PD deficiency, drug-induced haemolysis and bilirubin metabolism.

Overview & classification of glucose-6-phosphate fates

Glucose-6-phosphate (G6P) sits at a metabolic crossroads. From it, three non-glycolytic fates draw upon the same substrate:

• HMP shunt (pentose phosphate pathway, PPP) → NADPH + ribose-5-P
• Uronic acid (glucuronate) pathway → UDP-glucuronate, glucuronic acid, ascorbate (not in primates), xylulose
• Glycolysis / glycogenesis (the "default" routes)

High-yield: The HMP shunt, uronic acid pathway and glycolysis are all cytoplasmic. None of them require oxygen, and the HMP shunt + uronic acid pathway produce no ATP.

Feature	HMP shunt	Uronic acid pathway	Glycolysis
Major product	NADPH, ribose-5-P	Glucuronate, ascorbate (non-primate)	ATP, pyruvate
ATP yield	Nil	Nil	Net 2 (anaerobic)
Coenzyme made	NADPH	NADH	NADH, ATP
Rate-limiting enzyme	Glucose-6-P dehydrogenase	UDP-glucose dehydrogenase	PFK-1
Location	Cytoplasm	Cytoplasm	Cytoplasm

HMP shunt — the two phases

The pentose phosphate pathway has an irreversible oxidative phase and a reversible non-oxidative phase.

Oxidative (irreversible) phase

This phase generates 2 NADPH and CO₂ per glucose-6-P, ending in ribulose-5-phosphate.

G6P → 6-phosphogluconolactone → 6-phosphogluconate → ribulose-5-P + CO₂

1. Glucose-6-phosphate dehydrogenase (G6PD) — the rate-limiting and committed step; oxidises G6P to 6-phosphogluconolactone, producing the first NADPH. Inhibited by NADPH (product inhibition), stimulated by insulin (induction of the gene).
2. 6-phosphogluconolactonase — hydrolyses the lactone to 6-phosphogluconate.
3. 6-phosphogluconate dehydrogenase — oxidative decarboxylation to ribulose-5-P, producing the second NADPH and releasing CO₂ (the only step that releases CO₂ in the PPP).

High-yield: G6PD is the rate-limiting enzyme of the HMP shunt and its activity is governed by the NADP⁺/NADPH ratio. A high NADP⁺ (i.e. NADPH being consumed) drives the pathway.

Non-oxidative (reversible) phase

Ribulose-5-P is interconverted into ribose-5-P and xylulose-5-P, then sugars are shuffled by transketolase and transaldolase to regenerate glycolytic intermediates (fructose-6-P and glyceraldehyde-3-P). This phase lets the cell match output to demand — pure ribose for nucleotides, pure NADPH for biosynthesis, or both.

• Transketolase transfers a 2-carbon unit and requires thiamine pyrophosphate (TPP) + Mg²⁺.
• Transaldolase transfers a 3-carbon unit and needs no coenzyme.

High-yield: Erythrocyte transketolase activity (with/without added TPP) is the classic functional test for thiamine (B1) deficiency — an activation coefficient >25% indicates deficiency.

Mnemonic — non-oxidative reactions: "TK, TA, TK" (transketolase, transaldolase, transketolase) shuttle C5 sugars into C6 + C3.

The overall stoichiometry: 3 G6P + 6 NADP⁺ → 3 CO₂ + 2 fructose-6-P + glyceraldehyde-3-P + 6 NADPH.

Four metabolic situations the cell balances

The beauty of the dual-phase design is flexibility. Depending on whether the cell needs ribose, NADPH, or both, the pathway runs differently:

1. Ribose needed > NADPH (rapidly dividing cells): non-oxidative phase runs in reverse, converting glycolytic fructose-6-P and glyceraldehyde-3-P into ribose-5-P without generating NADPH or losing CO₂.
2. NADPH ≈ ribose needed: only the oxidative phase runs; ribose-5-P is the end product and NADPH is generated — ideal for cells synthesising nucleotides.
3. NADPH needed >> ribose: oxidative phase runs, then excess ribose-5-P is recycled to fructose-6-P and glyceraldehyde-3-P (re-enter glycolysis), maximising NADPH (e.g. adipose, lactating mammary gland).
4. NADPH and ATP both needed: ribose-5-P is converted to pyruvate via glycolysis after re-entering as fructose-6-P/glyceraldehyde-3-P.

High-yield: A stem describing a "rapidly proliferating tumour or bone marrow needing ribose for DNA but little NADPH" is pointing at the reversed non-oxidative phase producing ribose-5-P from glycolytic intermediates.

Functions of NADPH (why the shunt matters)

NADPH is reducing power for biosynthesis and protection, distinct from NADH (which fuels ATP synthesis).

• Reductive biosynthesis: fatty acid, cholesterol and steroid synthesis — hence high G6PD activity in liver, adipose tissue, adrenal cortex, lactating mammary gland, gonads, RBCs.
• Glutathione regeneration: NADPH keeps glutathione reduced (GSH) via glutathione reductase — the RBC's main antioxidant defence.
• Respiratory burst: NADPH oxidase in phagocytes generates superoxide for microbial killing (defective in chronic granulomatous disease).
• Cytochrome P450 mono-oxygenase reactions and drug/xenobiotic detoxification.
• Nitric oxide synthase and folate metabolism (methaemoglobin reductase indirectly).

High-yield: Tissues with low or absent HMP shunt activity include skeletal muscle (mostly glycolytic, little fatty acid synthesis). High-activity tissues are those doing fat/steroid synthesis or facing oxidative stress.

G6PD deficiency

The single most exam-relevant clinical correlate of the HMP shunt.

Genetics & epidemiology

• X-linked recessive → predominantly affects males; heterozygous females show mosaicism (lyonisation).
• Commonest enzymopathy worldwide (~400 million affected); confers partial protection against falciparum malaria, hence high prevalence in malarial belts.
• Variants: G6PD A− (African, milder, self-limited), G6PD Mediterranean (severe, also favism), G6PD Canton (Asian).

Pathophysiology

The RBC has no nucleus or mitochondria, so the HMP shunt is its only source of NADPH. Without NADPH, glutathione cannot be regenerated → oxidant stress overwhelms defences → Hb oxidation (Heinz bodies) and membrane damage → intravascular and extravascular haemolysis.

Oxidant trigger → ↓NADPH → ↓GSH → Hb denaturation → Heinz bodies → splenic "bite cells" → acute haemolytic anaemia

Clinical features & triggers

Episodic acute haemolytic anaemia — jaundice, dark urine (haemoglobinuria), pallor, back pain, 2–3 days after exposure. Neonatal jaundice is common.

Trigger category	Classic examples
Drugs	Primaquine, dapsone, sulphonamides, nitrofurantoin, quinolones, methylene blue
Infections	Any acute infection (commonest precipitant overall)
Foods	Fava beans (favism) — especially Mediterranean variant
Chemicals	Naphthalene (mothballs), rasburicase

Mnemonic — drugs to avoid: "Some Antimalarials Nibble Daily Surely" → Sulpha, Antimalarials (primaquine), Nitrofurantoin, Dapsone, Sulfasalazine.

Diagnosis

• Peripheral smear: bite cells, blister cells, Heinz bodies (with supravital stain like crystal violet/brilliant cresyl blue).
• Investigation of choice: quantitative G6PD enzyme assay (NADPH fluorescence/spectrophotometric).
• Screening: fluorescent spot test (Beutler test) — NADPH fluoresces under UV; no fluorescence = deficiency.

High-yield: Test for G6PD a few weeks after an acute haemolytic episode, not during it. During haemolysis the old deficient cells are destroyed and young reticulocytes (with higher enzyme) give a falsely normal result.

Management

• Avoid triggers (mainstay — there is no cure).
• Supportive care during crisis: hydration, transfusion if severe.
• Treat neonatal jaundice with phototherapy; exchange transfusion if severe.

G6PD vs other haemolytic enzymopathies (quick contrast)

Feature	G6PD deficiency	Pyruvate kinase deficiency
Inheritance	X-linked recessive	Autosomal recessive
Pathway affected	HMP shunt (NADPH)	Glycolysis (ATP)
Haemolysis pattern	Episodic, trigger-related	Chronic
Smear	Bite cells, Heinz bodies	Echinocytes ("burr cells"), no Heinz
2,3-BPG	Normal	Increased (right-shift, less symptomatic anaemia)

High-yield: Pyruvate kinase deficiency is the commonest enzyme defect of glycolysis causing hereditary non-spherocytic haemolytic anaemia, while G6PD is the commonest of the HMP shunt — a classic two-option MCQ pair.

Uronic acid (glucuronate) pathway

An alternative oxidative route of glucose that converts G6P → glucose-1-P → UDP-glucose → UDP-glucuronate, the active donor of glucuronic acid.

Key reactions & enzymes

UDP-glucose → (UDP-glucose dehydrogenase, NAD⁺-dependent) → UDP-glucuronate → glucuronate → gulonate → ... → L-xylulose → xylulose-5-P → enters HMP shunt

• UDP-glucose dehydrogenase is the regulated step; uses NAD⁺ (the pathway produces NADH, unlike the HMP shunt).
• In most mammals, gulonate → L-gulonolactone → ascorbic acid (vitamin C). Primates and guinea pigs lack L-gulonolactone oxidase, so they cannot synthesise vitamin C and must obtain it from diet.

Functions

• Conjugation/detoxification: UDP-glucuronate conjugates bilirubin (via UDP-glucuronyl transferase), steroids, and many drugs (e.g. paracetamol, morphine, chloramphenicol) to make them water-soluble for excretion.
• Proteoglycan/GAG synthesis: glucuronic acid is a building block of glycosaminoglycans (hyaluronic acid, heparin, chondroitin sulphate).

High-yield: Neonatal physiological jaundice results from immature UDP-glucuronyl transferase. Crigler-Najjar (absent/deficient) and Gilbert syndrome (reduced) are inherited defects of bilirubin glucuronidation → unconjugated hyperbilirubinaemia.

Essential pentosuria

A benign inherited disorder (autosomal recessive) due to deficiency of xylitol dehydrogenase (L-xylulose reductase), causing accumulation and urinary excretion of L-xylulose. It is harmless but classically gives a false-positive Benedict's test (reducing sugar in urine) — a common viva trap. No treatment needed.

Condition	Enzyme defect	Consequence
Essential pentosuria	L-xylulose reductase (xylitol DH)	Benign L-xylulosuria, +ve Benedict's
Crigler-Najjar I/II	UDP-glucuronyl transferase	Unconjugated hyperbilirubinaemia
Gilbert syndrome	↓UDP-glucuronyl transferase	Mild unconjugated hyperbilirubinaemia

Links to galactose and fructose metabolism

The job blurb ties the carbohydrate map together; these monosaccharide disorders are reliably examined.

Galactose metabolism

Galactose → (galactokinase) → galactose-1-P → (GALT) → UDP-galactose ⇌ UDP-glucose (epimerase)

Disorder	Deficient enzyme	Features
Classic galactosaemia	GALT (galactose-1-P uridyltransferase)	Vomiting, hepatomegaly, jaundice, E. coli sepsis, cataracts, intellectual disability
Galactokinase deficiency	Galactokinase	Cataracts only (no liver/brain disease)
Epimerase deficiency	UDP-galactose-4-epimerase	Variable, often benign

High-yield: Cataracts in galactosaemia and galactokinase deficiency are due to galactitol accumulation (galactose reduced by aldose reductase, osmotic lens swelling). Treatment of galactosaemia is lifelong galactose/lactose-free diet (remove milk).

Fructose metabolism

Fructose → (fructokinase) → fructose-1-P → (aldolase B) → DHAP + glyceraldehyde

Disorder	Deficient enzyme	Features
Essential fructosuria	Fructokinase	Benign, fructose in urine, +ve Benedict's
Hereditary fructose intolerance (HFI)	Aldolase B	Hypoglycaemia, vomiting, hepatic/renal failure after fructose/sucrose; fatal if untreated

High-yield: In HFI, fructose-1-P accumulates and traps phosphate → inhibits glycogenolysis and gluconeogenesis → severe hypoglycaemia. Management: strict avoidance of fructose, sucrose and sorbitol.

Key differentials & integration

When a stem describes "reducing substance in urine + benign," think the harmless trio: essential pentosuria, essential fructosuria, and lactosuria of pregnancy. When it describes haemolysis after a drug in a male child → G6PD deficiency. When it describes a neonate with cataracts and E. coli sepsis after milk → galactosaemia.

• Heinz bodies also appear in unstable haemoglobinopathies and NADPH methaemoglobin reductase pathway issues — but bite cells point to G6PD.
• Differentiate NADPH (HMP shunt; biosynthesis/antioxidant) from NADH (glycolysis/uronic pathway; ATP via ETC).

Complications

• G6PD deficiency: acute haemolytic crisis, acute kidney injury from haemoglobinuria, neonatal kernicterus, rarely chronic non-spherocytic haemolytic anaemia (severe variants).
• Galactosaemia: cataracts, cirrhosis, intellectual disability, gram-negative neonatal sepsis, premature ovarian failure.
• HFI: hepatic failure, renal tubular acidosis (Fanconi-like), hypoglycaemic seizures.

Recently asked / exam angle

• Rate-limiting enzyme of HMP shunt → Glucose-6-phosphate dehydrogenase (repeatedly asked).
• Which coenzyme/vitamin does transketolase need? → Thiamine (TPP); basis of RBC transketolase test for B1 deficiency.
• Which step releases CO₂ in PPP? → 6-phosphogluconate dehydrogenase.
• Why are RBCs uniquely vulnerable in G6PD deficiency? → HMP shunt is their sole NADPH source.
• When to assay G6PD? → not during acute haemolysis (false-normal due to reticulocytosis).
• Enzyme defect in essential pentosuria → L-xylulose reductase (xylitol dehydrogenase).
• Why can't humans synthesise vitamin C? → lack of L-gulonolactone oxidase in the uronic acid pathway.
• Cataract-only galactose disorder → galactokinase deficiency (galactitol).
• Drug requiring NADPH that can be dangerous in G6PD? → methylene blue (avoid; can paradoxically cause haemolysis).
• NADPH oxidase defect disease → chronic granulomatous disease (links HMP shunt product to immunology).

Rapid revision

1. HMP shunt = cytoplasmic, no ATP, makes NADPH + ribose-5-P.
2. G6PD is rate-limiting; regulated by NADP⁺/NADPH ratio; induced by insulin.
3. Oxidative phase yields 2 NADPH + 1 CO₂; non-oxidative phase is reversible (transketolase/transaldolase).
4. Transketolase needs TPP (thiamine); transaldolase needs no coenzyme.
5. NADPH functions: fatty acid/steroid synthesis, GSH regeneration, respiratory burst, P450.
6. G6PD deficiency is X-linked, commonest enzymopathy, protects against malaria.
7. Smear shows bite cells, blister cells, Heinz bodies; diagnose by enzyme assay after the crisis.
8. Triggers: primaquine, dapsone, sulphonamides, nitrofurantoin, fava beans, naphthalene, infection.
9. Uronic acid pathway makes UDP-glucuronate for bilirubin/drug conjugation and GAG synthesis; primates can't make vitamin C (no L-gulonolactone oxidase).
10. Essential pentosuria (L-xylulose reductase deficiency) = benign, +ve Benedict's.
11. Galactosaemia (GALT) → cataracts (galactitol), E. coli sepsis; galactokinase defect = cataracts only.
12. HFI (aldolase B) → hypoglycaemia, liver failure; avoid fructose/sucrose/sorbitol.